Absence of CCL2 and CCL3 Ameliorates Central Nervous System Grey Matter But Not White Matter Demyelination in the Presence of an Intact Blood–Brain Barrier

被引:0
作者
Katharina Janssen
Mira Rickert
Tim Clarner
Cordian Beyer
Markus Kipp
机构
[1] RWTH Aachen University,Institute of Neuroanatomy, Faculty of Medicine
[2] Ludwig-Maximilians-University of Munich,Department of Anatomy II
来源
Molecular Neurobiology | 2016年 / 53卷
关键词
Chemokines; CNS; Cuprizone; Multiple sclerosis;
D O I
暂无
中图分类号
学科分类号
摘要
A broad spectrum of diseases is characterized by myelin abnormalities, oligodendrocyte pathology, and concomitant glia activation, among multiple sclerosis (MS). Our knowledge regarding the factors triggering gliosis and demyelination is scanty. Chemokines are pivotal for microglia and astrocyte activation and orchestrate critical steps during the formation of central nervous system (CNS) demyelinating lesions. Redundant functions of chemokines complicate, however, the study of their functional relevance. We used the cuprizone model to study redundant functions of two chemokines, CCL2/MCP1 and CCL3/MIP1α, which are critically involved in the pathological process of cuprizone-induced demyelination. First, we generated a mutant mouse strain lacking functional genes of both chemokines and demonstrated that double-mutant animals are viable, fertile, and do not present with gross abnormalities. Astrocytes and peritoneal macrophages, cultured form tissues of these animals did neither express CCL2 nor CCL3. Exposure to cuprizone resulted in increased CCL2 and CCL3 brain levels in wild-type but not mutant animals. Cuprizone-induced demyelination, oligodendrocyte loss, and astrogliosis were significantly ameliorated in the cortex but not corpus callosum of chemokine-deficient animals. In summary, we provide a novel powerful model to study the redundant function of two important chemokines. Our study reveals that chemokine function in the CNS redounds to region-specific pathophysiological events.
引用
收藏
页码:1551 / 1564
页数:13
相关论文
共 227 条
[1]  
van der Valk P(2000)Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS Neuropathol Appl Neurobiol 26 2-10
[2]  
De Groot CJ(2005)Multiple sclerosis pathology: evolution of pathogenetic concepts Brain Pathol 15 217-222
[3]  
Lassmann H(1946)Rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of brain tissue with adjuvants Science 104 362-363
[4]  
Kabat EA(1995)Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant J Neuroimmunol 63 193-205
[5]  
Wolf A(2012)In vitro and in vivo models of multiple sclerosis CNS Neurol Disord Drug Targets 11 570-588
[6]  
Bezer AE(2011)Multiple sclerosis is not a disease of the immune system Q Rev Biol 86 287-321
[7]  
Lorentzen JC(2010)Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis Arch Immunol Ther Exp (Warsz) 58 325-333
[8]  
van der Star BJ(2012)Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy Clin Rev Allergy Immunol 42 26-34
[9]  
Vogel DY(2013)Pathoetiology of multiple sclerosis: are we barking up the wrong tree? F1000Prime Rep 5 20-468
[10]  
Kipp M(2004)Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion Ann Neurol 55 458-1483